Cargando…

Cancer organoid applications to investigate chemotherapy resistance

In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Kenji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792487/
https://www.ncbi.nlm.nih.gov/pubmed/36582205
http://dx.doi.org/10.3389/fmolb.2022.1067207
_version_ 1784859644790833152
author Harada, Kenji
Sakamoto, Naoya
author_facet Harada, Kenji
Sakamoto, Naoya
author_sort Harada, Kenji
collection PubMed
description In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique that simulates the in vivo environment in vitro, especially in the quickly developing fields of anticancer drug resistance, drug-tolerant persisters, and drug screening. This review provides an overview of organoid technology, the use of organoids in the field of anticancer drug resistance research, their relevance to clinical information and clinical trials, and approaches to automation and high throughput.
format Online
Article
Text
id pubmed-9792487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97924872022-12-28 Cancer organoid applications to investigate chemotherapy resistance Harada, Kenji Sakamoto, Naoya Front Mol Biosci Molecular Biosciences In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique that simulates the in vivo environment in vitro, especially in the quickly developing fields of anticancer drug resistance, drug-tolerant persisters, and drug screening. This review provides an overview of organoid technology, the use of organoids in the field of anticancer drug resistance research, their relevance to clinical information and clinical trials, and approaches to automation and high throughput. Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9792487/ /pubmed/36582205 http://dx.doi.org/10.3389/fmolb.2022.1067207 Text en Copyright © 2022 Harada and Sakamoto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Harada, Kenji
Sakamoto, Naoya
Cancer organoid applications to investigate chemotherapy resistance
title Cancer organoid applications to investigate chemotherapy resistance
title_full Cancer organoid applications to investigate chemotherapy resistance
title_fullStr Cancer organoid applications to investigate chemotherapy resistance
title_full_unstemmed Cancer organoid applications to investigate chemotherapy resistance
title_short Cancer organoid applications to investigate chemotherapy resistance
title_sort cancer organoid applications to investigate chemotherapy resistance
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792487/
https://www.ncbi.nlm.nih.gov/pubmed/36582205
http://dx.doi.org/10.3389/fmolb.2022.1067207
work_keys_str_mv AT haradakenji cancerorganoidapplicationstoinvestigatechemotherapyresistance
AT sakamotonaoya cancerorganoidapplicationstoinvestigatechemotherapyresistance